166 related articles for article (PubMed ID: 30981987)
21. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide cell-free DNA fragmentation in patients with cancer.
Cristiano S; Leal A; Phallen J; Fiksel J; Adleff V; Bruhm DC; Jensen SØ; Medina JE; Hruban C; White JR; Palsgrove DN; Niknafs N; Anagnostou V; Forde P; Naidoo J; Marrone K; Brahmer J; Woodward BD; Husain H; van Rooijen KL; Ørntoft MW; Madsen AH; van de Velde CJH; Verheij M; Cats A; Punt CJA; Vink GR; van Grieken NCT; Koopman M; Fijneman RJA; Johansen JS; Nielsen HJ; Meijer GA; Andersen CL; Scharpf RB; Velculescu VE
Nature; 2019 Jun; 570(7761):385-389. PubMed ID: 31142840
[TBL] [Abstract][Full Text] [Related]
23. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
Chen M; Zhao H
Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 cases.
Liang W; Liu D; Li M; Wang W; Qin Z; Zhang J; Zhang Y; Hu Y; Bao H; Xiang Y; Wang B; Wu J; Sun J; Hu C; Ye X; Zhang X; Xiao W; Yun C; Sun D; Wang W; Chang N; Zhang Y; Zhao J; Zhang X; Xu J; Wu D; Liu X; Guo Y; Zhang Q; Zhang W; Yang L; Li Z; Zhang X; Han B; Tong Z; He J; Qu J; Fan JB; Zhong N
Transl Lung Cancer Res; 2020 Oct; 9(5):2016-2026. PubMed ID: 33209621
[TBL] [Abstract][Full Text] [Related]
25. RNF213 gene mutation in circulating tumor DNA detected by targeted next-generation sequencing in the assisted discrimination of early-stage lung cancer from pulmonary nodules.
Jiang N; Zhou J; Zhang W; Li P; Liu Y; Shi H; Zhang C; Wang Y; Zhou C; Peng C; Zhang W; Hao Y; Sun Q; Li Y; Zhao X
Thorac Cancer; 2021 Jan; 12(2):181-193. PubMed ID: 33200540
[TBL] [Abstract][Full Text] [Related]
26. Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review.
Esagian SM; Grigoriadou GΙ; Nikas IP; Boikou V; Sadow PM; Won JK; Economopoulos KP
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2051-2066. PubMed ID: 32462295
[TBL] [Abstract][Full Text] [Related]
27. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
[TBL] [Abstract][Full Text] [Related]
29. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
[TBL] [Abstract][Full Text] [Related]
30. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Horn L; Whisenant JG; Wakelee H; Reckamp KL; Qiao H; Leal TA; Du L; Hernandez J; Huang V; Blumenschein GR; Waqar SN; Patel SP; Nieva J; Oxnard GR; Sanborn RE; Shaffer T; Garg K; Holzhausen A; Harrow K; Liang C; Lim LP; Li M; Lovly CM
J Thorac Oncol; 2019 Nov; 14(11):1901-1911. PubMed ID: 31446141
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer.
Lyu M; Zhou J; Ning K; Ying B
Onco Targets Ther; 2019; 12():2539-2552. PubMed ID: 31040697
[TBL] [Abstract][Full Text] [Related]
32. Integrating genomic features for non-invasive early lung cancer detection.
Chabon JJ; Hamilton EG; Kurtz DM; Esfahani MS; Moding EJ; Stehr H; Schroers-Martin J; Nabet BY; Chen B; Chaudhuri AA; Liu CL; Hui AB; Jin MC; Azad TD; Almanza D; Jeon YJ; Nesselbush MC; Co Ting Keh L; Bonilla RF; Yoo CH; Ko RB; Chen EL; Merriott DJ; Massion PP; Mansfield AS; Jen J; Ren HZ; Lin SH; Costantino CL; Burr R; Tibshirani R; Gambhir SS; Berry GJ; Jensen KC; West RB; Neal JW; Wakelee HA; Loo BW; Kunder CA; Leung AN; Lui NS; Berry MF; Shrager JB; Nair VS; Haber DA; Sequist LV; Alizadeh AA; Diehn M
Nature; 2020 Apr; 580(7802):245-251. PubMed ID: 32269342
[TBL] [Abstract][Full Text] [Related]
33. Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
Fu Y; Wang A; Zhou J; Feng W; Shi M; Xu X; Zhao H; Cai L; Feng J; Lv X; Zhang X; Xu W; Zhang Z; Ma G; Wang J; Zhou T; Zhao D; Fang H; Liu Z; Huang JA
Front Oncol; 2021; 11():621992. PubMed ID: 33718183
[TBL] [Abstract][Full Text] [Related]
34. A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for
Shin JY; Kim JO; Lee MR; Kim SR; Beck KS; Kang JH
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33266057
[TBL] [Abstract][Full Text] [Related]
35. Peptide-Affinity Precipitation of Extracellular Vesicles and Cell-Free DNA Improves Sequencing Performance for the Detection of Pathogenic Mutations in Lung Cancer Patient Plasma.
Taylor C; Chacko S; Davey M; Lacroix J; MacPherson A; Finn N; Wajnberg G; Ghosh A; Crapoulet N; Lewis SM; Ouellette RJ
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260345
[TBL] [Abstract][Full Text] [Related]
36.
Nacchio M; Sgariglia R; Gristina V; Pisapia P; Pepe F; De Luca C; Migliatico I; Clery E; Greco L; Vigliar E; Bellevicine C; Russo A; Troncone G; Malapelle U
J Thorac Dis; 2020 Jul; 12(7):3836-3843. PubMed ID: 32802465
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal Monitoring of
Li N; Guha U; Kim C; Ye L; Cheng J; Li F; Chia D; Wei F; Wong DTW
Front Oncol; 2020; 10():1240. PubMed ID: 32793495
[No Abstract] [Full Text] [Related]
38. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Romero A; Serna-Blasco R; Alfaro C; Sánchez-Herrero E; Barquín M; Turpin MC; Chico S; Sanz-Moreno S; Rodrigez-Festa A; Laza-Briviesca R; Cruz-Bermudez A; Calvo V; Royuela A; Provencio M
Transl Lung Cancer Res; 2020 Jun; 9(3):532-540. PubMed ID: 32676317
[TBL] [Abstract][Full Text] [Related]
39. Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients.
Chiou CC; Wang CL; Luo JD; Liu CY; Ko HW; Yang CT
Cancer Genomics Proteomics; 2020; 17(4):417-423. PubMed ID: 32576586
[TBL] [Abstract][Full Text] [Related]
40. Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
Bonanno L; Pavan A; Ferro A; Calvetti L; Frega S; Pasello G; Aprile G; Guarneri V; Conte P;
Oncologist; 2020 Dec; 25(12):e1996-e2005. PubMed ID: 32557976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
